Key Business Performance and Highlights
CSL continues to deliver on its strategy, with an 9%# increase in total revenue. The strength of our results reflects the execution of our strategic plan and patient-focussed workforce.
| |
|
|
|
GROWTH
- Another strong year with revenue up 9%^ and reported net profit after tax of US$2,103 million, up 17% at constant currency (CC)^.
- Our largest franchise, the immunoglobulin portfolio, performed extremely well, with PRIVIGEN® sales growing 20%^ and HIZENTRA® sales up 34%^.
- Seqirus’ earnings before interest and taxes grew more than 70% this year underpinned by sales of new and differentiated products - FLUCELVAX® and FLUAD®.
|
|
|
EFFICIENCY
- Major capital projects underway at all manufacturing sites to support future demand.
- 40 new plasma collection centres opened in the United States (US).
- Strategic review of end-to-end supply logistics.
- Strategic partnership with Thermo Fisher Scientific for lease of CSL’s Lengnau, Switzerland, biotech manufacturing facility.
- Direct distribution transition in China now complete.
- Underwent 401 regulatory inspections of our manufacturing facilities* with no impact to licences or operations.
|
|
|
INFLUENZA
- Total revenue up 11% at CC basis driven by our seasonal influenza vaccines, with a significant increase in demand for FLUAD®, Seqirus’ adjuvanted influenza vaccine for the elderly market and increased sales of
FLUCELVAX® Quadrivalent influenza vaccine.
|
|
|
INNOVATION
- Acquired Vitaeris to expedite the development of Clazakizumab – an anti-interleukin-6 monoclonal antibody for the treatment of chronic antibody-mediation rejection (or AMR) in kidney transplant recipients.
- Agreement to acquire the late stage gene therapy candidate for the treatment of haemophilia B from uniQure.
- Futility test for CSL112 was completed with the recommendation that the trial should continue (currently in Phase III for cardiovascular disease).
- Achieved 29 product registrations or new indications in numerous countries.
|
|
|
PEOPLE & CULTURE
- CSL named in Best Employers for Diversity (Forbes).
- Employee workforce up 7%, with 57% of our employee base female.
- Achieved 76% employee engagement score, up 2.4 points on prior year.
|
|
|
SHARED VALUE
- US$8.8 billion distributed in supplier payments, employee wages and benefits, shareholder returns, government taxes and community contributions.
- US$38.7 million in global community investment across our strategic areas of support.
|
^Constant currency removes the impact of exchange rate movements, facilitating comparability of operational performance. For further detail please refer to page 16.
*Does not include Ruide. Limited assurance by Ernst & Young.
More here on CSL.com (Our Company > Corporate Responsibility)
